Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health is well-positioned for future growth as it continues to expand its offerings in the value-based healthcare industry. The company's strong financial performance, with increasing revenues and adjusted EBITDA estimates, is a testament to its leadership in this growing market. With a diverse range of solutions and contracts in its portfolio, Evolent's reliable implementation and successful cross-selling strategies demonstrate its ability to drive long-term growth.

Bears say

Evolent Health is in a back-half weighted year with its FY26 revenue and adjusted EBITDA guidance reaffirmed, indicating limited growth potential. The company's underperformance in 1Q26 shows concerns about its ability to achieve its own targets and compete with other players in the industry. Furthermore, the high concentration risk with Cook County, Illinois and other relationships poses significant risks to the company's financial stability and long-term growth prospects, warranting a negative outlook on the stock.

Evolent Health (EVH) has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 13 analysts, Evolent Health (EVH) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.